The purpose of this study is to determine how well losartan reduces inflammation and fibrosis to improve immune system recovery. Sep 17, 2012 losartan cozaar is an angiotensin at1 receptor antagonist. Based on the reduction of endpoints in niddm with the angiotensin ii antagonist losartan renaal study, losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with type 2 diabetes. Losartan vs atenolol, in those with htn, dm, lvhmore effective in reducing. Jan 04, 2018 the life study was a multinational, doubleblind study comparing losartan potassium and atenolol in 9193 hypertensive patients with ecgdocumented left ventricular hypertrophy. The findings from one such trial, the losartan intervention for endpoint reduction in hypertension life study, were recently published and offer important insights into the workings of this drug class.
The effects of losartan compared to atenolol on stroke in. The losartan intervention for endpoint reduction life in hypertension study is a doubleblind, prospective, parallel group study designed to compare the effects of losartan with those of the betablocker atenolol on the reduction of cardiovascular morbidity and mortality in approximately 8,300 hypertensive patients initial sitting diastolic. Nieminen, per omvik, suzanne oparil, hans wedel for the life study group, the losartan intervention for endpoint reduction life in hypertension study. Costeffectiveness of losartan versus atenolol in treating. Losartan for the treatment of hypertension and left. Efficacy and tolerability of losartan in patients with essential. The primary aim of the life study was to deter mine if selective at1receptor antagonism with losartan would be more effective than. The effect of losartan versus atenolol on cardiovascular. Costeffectiveness of losartanbased therapy in patients. Pdf life losartan intervention for endpoint reduction in. The reduction of endpoints in niddm with the angiotensin ii antagonist losartan study was an investigatorinitiated, multinational, doubleblind, randomized, placebocontrolled study.
Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study life. Effects of losartan on cardiovascular morbidity and mortality. Oct 25, 2003 lars lindholm and colleagues aug 23, p 6191 suggest that losartan is better than atenolol in reducing sudden cardiac death in diabetic hypertensives with leftventricular hypertrophy. Pdf the effects of losartan compared to atenolol on. Effects of losartan or atenolol in hypertensive patients. Cardiovascular morbidity and mortality in the losartan intervention. Pdf costeffectiveness of losartan versus atenolol in. Dailymed losartan potassium and hydrochlorothiazide tablet. Losartan intervention for endpoint reduction life in.
The life trial compared the effectiveness of losartan and atenolol on bp lowering, lvh, and cvd morbidity and mortality in 9193 patients with hypertension and lvh aged 5580 years followed up for 4. Costeffectiveness of losartanbased therapy in patients with. It competitively blocks the at1 receptor where angiotensin ii is attached and. Losartan hctz is a well tolerated combination therapy. The losartan intervention for endpoint reduction in hypertension life study reported that a losartan based antihypertensive regimen reduced cardiovascular morbidity and mortality composite of cardiovascular death, stroke, and myocardial. The effect of losartan compared with atenolol on the. The life years saved by losartan through stoke reduction were 0. Sep 17, 2012 in the life study, losartan based therapy was associated with a lower incidence of cardiovascular morbidity and mortality than atenololbased therapy, mainly as a result of a reduced risk of stroke. Effects of losartan on renal and cardiovascular outcomes.
Intervention for endpoint reduction in hypertension study life. Aug 05, 2003 the losartan intervention for endpoint reduction in hypertension life study. This conclusion is based on an analysis of the patients with diabetes enrolled in the losartan intervention for endpoint reduction in hypertension life study. The lifeyears saved by losartan through stoke reduction were 0. This study is ongoing, but not recruiting participants. It is approved in numerous countries for the treatment of hypertension and has been approved in the uk, the us and several european countries for stroke risk reduction in patients with hypertension and left ventricular hypertrophy lvh. The losartan intervention for endpoint reduction in hypertension life study. Previous reports concluded, however, that the number of pvc should be reduced by 6590% after the treatment when the effect was truly attributable to the agent. Approximately onefifth of the superiority of losartan versus atenolol on the primary composite end point in the life study was due to its effect on albuminuria. The losartan intervention for endpoint reduction life. Losartan decreased premature ventricular contractions in. Losartan may also be used for purposes not listed in this medication guide. Dec 18, 2018 losartan potassium is a drug that effectively treats high blood pressure and diabetic neuropathy. Losartan fda prescribing information, side effects and uses.
Costeffectiveness of losartan versus atenolol in treating hypertensionan analysis of the life study from a swiss perspective article pdf available in cardiovascular drugs and therapy 185. Several drugs can achieve this goal and consequently many different pharmacological targets are in play. An economic assessment of losartanbased versus atenololbased therapy in patients with hypertension and leftventricular hypertrophy. Mar 30, 2006 the life study design has been previously published. The terminal half life of losartan is about 2 hours and of the metabolite is about 69 hours.
Losartan is recommended for use alone or with hydrochlorothiazide, but it can also be. A detailed description of study design has been published elsewhere. Jun 15, 2018 the life trial compared the effectiveness of losartan and atenolol on bp lowering, lvh, and cvd morbidity and mortality in 9193 patients with hypertension and lvh aged 5580 years followed up for 4. Treatment with losartan in the life study resulted in a greater reduction in albuminuria compared with atenolol for the same reduction in blood pressure.
The losartan intervention for endpoint reduction life triala. A bioequivalence study of losartan potassium tablets. Life losartan intervention for endpoint reduction in hypertension study and its substudies. The losartan intervention for endpoint reduction life trial. Fifteen years of life losartan intervention for endpoint. Dailymed losartan potassium 25 mg losartan potassium. Losartan was the first available selective at 1receptor antagonist. The study demonstrated that in type ii diabetic patients already receiving conventional antihypertensive therapy, the use of the angiotensiniireceptor antagonist losartan significantly decreased the risk of esrd 19.
The losartan intervention for endpoint reduction in hypertension life study demonstrated that losartan based therapy reduced cardiovascular end points significantly better than atenololbased therapy for a similar reduction in blood pressure bp in patients with hypertension and left ventricular hypertrophy lvh. So, life study was the first comparative trial in which a newer anti hypertensive. Nov 21, 2019 evaluate the clinical response to losartan potassium and hydrochlorothiazide tablets 5012. In the losartan intervention for endpoint reduction life in hypertension study, 9193 patients with hypertension and left ventricular hypertrophy were randomized to losartan 50 mg plus hctz 12. Losartan is well tolerated in patients with heart failure than other arbs generic name. The active metabolite is 10 to 40 times more potent by weight than. The losartan intervention for endpoint reduction in hypertension life study reported that a losartanbased antihypertensive regimen reduced cardiovascular morbidity and mortality composite of cardiovascular death, stroke, and myocardial infarction more than therapy based on atenolol in patients with left ventricular hyper. It is also used to lower the risk of stroke in certain people with heart disease. General description losartan belongs to angiotensin receptor blockers. Losartanhctz is a well tolerated combination therapy. In the life study, black patients treated with atenolol were at a lower risk of experiencing cardiovascular events compared with black patients receiving losartan. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study life. Cozaar mechanism of action captopril is angiotensin ii receptor blocker. Capitals indicate lifethreatening, underlines indicate most frequent.
The losartan intervention for endpoint reduction in hypertension study life is the only completed hypertension trial of an arb to assess cardiovascular outcomes. The losartan intervention for endpoint reduction in hypertension life study showed that similar bp reduction can be achieved by choosing either. The end point findings from the life study are of interest in particular, a 25% reduction in stroke rate with losartan compared to the atenolol group. Pdf a study of losartan, alone or with hydrochlorothiazide. Patients with myocardial infarction or stroke within six months prior to randomization were excluded. Cozaar losartan potassium tablets page 2 of 28 do not exhibit any partial agonist activity at the at1 receptor and have much greater affinity about fold for the at1 receptor than for the at2 receptor. Mar 23, 2002 cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study life. Mar 09, 2018 a bioequivalence study of losartan potassium tablets containing losartan potassium 100 mg in normal, healthy, adults under fasting conditions the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. May 31, 2007 ultimately, hard end point trials are needed to provedisprove the merit of a drug class. The losartan intervention for endpoint reduction life in.
The life study was a multinational, doubleblind study comparing losartan potassium and atenolol in 9193 hypertensive patients with ecgdocumented left ventricular hypertrophy. The life study design has been previously published. Losartan is used to treat high blood pressure hypertension. Dec 05, 2018 losartan is used to treat high blood pressure hypertension. Neither losartan nor its metabolite accumulate in plasma upon repeated oncedaily dosing. A study of losartan, alone or with hydrochlorothiazide vs nifedipine gits in elderly patients with diastolic hypertension article pdf available in journal of human hypertension 1210. Common questions and answers about losartan life study. Atenolol and losartanbased therapy reduced bp similarly cumulative difference in mean brachial blood pressure 0. The losartan intervention for endpoint reduction life in hypertension study. Ultimately, hard end point trials are needed to provedisprove the merit of a drug class. Longterm use and tolerability of irbesartan for control of. The losartan intervention for endpoint reduction in hypertension life study reported that a losartan based antihypertensive regimen reduced cardiovascular morbidity and mortality composite of cardiovascular death, stroke, and myocardial infarction more than therapy based on atenolol in patients with left ventricular hyper. On the visual analogue scale, the mean quality of life was 71.
Losartan also significantly decreased the degree of proteinuria p life in hypertension study is a doubleblind, prospective, parallel group study designed to compare the effects of losartan with those of the betablocker atenolol on the reduction of cardiovascular morbidity and mortality in approximately 8,300 hypertensive patients initial sitting diastolic. The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 mg and do not change over time. Pdf life losartan intervention for endpoint reduction. This article provides an overview of the benefits, effectiveness, side effects, and warnings. In the life study, losartanbased therapy was associated with a lower incidence of cardiovascular morbidity and mortality than atenololbased therapy, mainly as a result of a reduced risk of stroke. Lars lindholm and colleagues aug 23, p 6191 suggest that losartan is better than atenolol in reducing sudden cardiac death in diabetic hypertensives with leftventricular hypertrophy. The primary hypothesis of the life study was that selective angiotensinii type 1receptor antagonism with losartan would be more effective than.
Effects of losartan on renal and cardiovascular outcomes in. Losartan is used to slow longterm kidney damage in people with type 2 diabetes who also have high blood pressure. Cardiovascular morbidity and mortality in the losartan. In the overall life study population n9193, treatment with losartan potassium resulted in a. A bioequivalence study of losartan potassium tablets containing losartan potassium 100 mg in normal, healthy, adults under fasting conditions the safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
88 170 1416 849 1075 315 1500 236 944 194 345 602 843 139 122 1286 731 1473 1398 835 1177 1057 641 964 277 673 421 573 642 296 450 1493